The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents

(2013) Axel Finckh et al.   ANNALS OF INTERNAL MEDICINE

Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis

(2012) P Livermore et al.   Pediatric Rheumatology

Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?

(2010) Randy Q Cron et al.   Pediatric Rheumatology

Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: Time for a consolidated patient registry

(2010) Meredith Y. Smith et al.   ARTHRITIS CARE & RESEARCH

Adult Outcomes of Patients with Juvenile Idiopathic Arthritis

(2009) Kirsten Minden   HORMONE RESEARCH

Anakinra for Systemic Juvenile Arthritis

(2009) Andrew Zeft et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

(2009) R. A.G. RUSSO et al.   JOURNAL OF RHEUMATOLOGY

Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist

(2009) Scott Canna et al.   Pediatric Rheumatology

The National Institutes of Health and the Best Pharmaceuticals for Children Act

(2009) Anne Zajicek   PEDIATRIC DRUGS

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

(2008) Norman Ilowite et al.   CLINICAL RHEUMATOLOGY

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET

Early effects of Anakinra in corticosteroid naïve SOJIA patients

(2008) NM Wulffraat et al.   Pediatric Rheumatology

Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS)

(2008) P Quartier et al.   Pediatric Rheumatology

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF

(2008) I Pontikaki et al.   Pediatric Rheumatology

Defining off-label and unlicensed use of medicines for children: Results of a Delphi survey

(2008) A NEUBERT et al.   PHARMACOLOGICAL RESEARCH

A case of macrophage activation syndrome successfully treated with anakinra

(2008) Alison Kelly et al.   Nature clinical practice. Rheumatology